News

Filter

Current filters:

Merck & Coodanacatib

ASBMR 2012: Anabolics and post-marketing studies

25-10-2012

This year's American Society for Bone and Mineral Research (ASBMR) conference, held in Minneapolis, Minnesota,…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEli LillyMerck & CoodanacatibPharmaceuticalProliaResearchteriparatideUnigene Labs

New data on Amgen's Prolia and Merck & Co's odanacatib presented at ASBMR meeting

15-10-2012

Amgen (Nasdaq: AMGN), the world's largest biotech firm, has presented data from several Prolia (denosumab)…

AmgenAnti-Arthritics/RheumaticsBiotechnologyMerck & CoodanacatibPharmaceuticalProliaResearchWomen's Health

Merck & Co closes odanacatib trial early on good results in osteoporosis

13-07-2012

US drug giant Merck & Co (NYSE: MRK) says it is halting a Phase III trial of its investigational osteoporosis…

Anti-Arthritics/RheumaticsMerck & CoodanacatibPharmaceuticalRegulationResearch

Back to top